Yeast two-hybrid methods and their applications in drug discovery.

The yeast two-hybrid (Y2H) method was first described over 20 years ago. It soon appeared as a major methodological breakthrough in the discovery and analysis of protein interactions, which play a pivotal role in all biological phenomena. Since its inception the Y2H method has constantly evolved and has inspired various assays that have found multiple applications of interest for drug discovery. Y2H methods are used to identify and validate therapeutic targets, discover protein interaction modulators, identify drug targets, and select combinatorial recognition molecules, which themselves find a wide range of applications. We review here the different transcriptional Y2H methods that are directly useful to drug discovery. Most should be increasingly used in the future as they continue to evolve to harness other methodological and conceptual advances.

[1]  M. Bickle,et al.  A RasGAP SH3 Peptide Aptamer Inhibits RasGAP-Aurora Interaction and Induces Caspase-Independent Tumor Cell Death , 2008, PloS one.

[2]  P. Colas.  The eleven-year switch of peptide aptamers , 2008, Journal of biology.

[3]  S. Muyldermans,et al.  Recent developments in engineering and delivery of protein and antibody therapeutics. , 2011, Current opinion in biotechnology.

[4]  A. Vazquez,et al.  Epstein–Barr virus and virus human protein interaction maps , 2007, Proceedings of the National Academy of Sciences.

[5]  Chi P. Ndi,et al.  A Novel Natural Product Compound Enhances cAMP-Regulated Chloride Conductance of Cells Expressing CFTRΔF508 , 2002, Molecular medicine.

[6]  R. Brent,et al.  Targeted modification and transportation of cellular proteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G L French,et al.  The continuing crisis in antibiotic resistance. , 2010, International journal of antimicrobial agents.

[8]  T. Berg.  Small-molecule inhibitors of protein-protein interactions. , 2008, Current opinion in drug discovery & development.

[9]  A. Barabasi,et al.  High-Quality Binary Protein Interaction Map of the Yeast Interactome Network , 2008, Science.

[10]  Michael Gribskov,et al.  A Physical Interaction Network of Dengue Virus and Human Proteins* , 2011, Molecular & Cellular Proteomics.

[11]  A. Reymond,et al.  p16 proteins from melanoma-prone families are deficient in binding to Cdk4. , 1995, Oncogene.

[12]  N. Saxena,et al.  RAS: Target for Cancer Therapy , 2008, Cancer investigation.

[13]  J. Camarero,et al.  Protein Microarrays: Novel Developments and Applications , 2010, Pharmaceutical Research.

[14]  H. Lehrach,et al.  A Human Protein-Protein Interaction Network: A Resource for Annotating the Proteome , 2005, Cell.

[15]  M. Baccarini,et al.  Raf kinases in cancer–roles and therapeutic opportunities , 2011, Oncogene.

[16]  J. Rain,et al.  Characterization of single chain antibody targets through yeast two hybrid , 2010, BMC biotechnology.

[17]  P. Aloy,et al.  Unveiling the role of network and systems biology in drug discovery. , 2010, Trends in pharmacological sciences.

[18]  Michael Albers,et al.  Automated Yeast Two-hybrid Screening for Nuclear Receptor-interacting Proteins*S , 2005, Molecular & Cellular Proteomics.

[19]  A. Barabasi,et al.  Interactome Networks and Human Disease , 2011, Cell.

[20]  John P. Overington,et al.  How many drug targets are there? , 2006, Nature Reviews Drug Discovery.

[21]  Philippe Roche,et al.  Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). , 2011, Current opinion in chemical biology.

[22]  C. Rudin,et al.  A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC). , 2010 .

[23]  Uwe Sauer,et al.  From good old biochemical analyses to high-throughput omics measurements and back. , 2011, Current opinion in biotechnology.

[24]  Jodi R Parrish,et al.  Yeast two-hybrid contributions to interactome mapping. , 2006, Current opinion in biotechnology.

[25]  Paul A. Bates,et al.  Global topological features of cancer proteins in the human interactome , 2006, Bioinform..

[26]  Nobuyoshi Sugaya,et al.  Assessing the druggability of protein-protein interactions by a supervised machine-learning method , 2009, BMC Bioinformatics.

[27]  Jonathan C. Fuller,et al.  Predicting druggable binding sites at the protein-protein interface. , 2009, Drug discovery today.

[28]  N. Hacohen,et al.  A Physical and Regulatory Map of Host-Influenza Interactions Reveals Pathways in H1N1 Infection , 2009, Cell.

[29]  Jonathan A. Cooper,et al.  Identification of radicicol as an inhibitor of in vivo Ras/Raf interaction with the yeast two-hybrid screening system. , 1998, The Journal of antibiotics.

[30]  M. Hirst,et al.  A two-hybrid system for transactivator bait proteins , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  S. Schreiber,et al.  A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Igor Stagljar,et al.  Two-hybrid technologies in proteomics research. , 2008, Current opinion in biotechnology.

[33]  W. Marasco,et al.  Intracellular antibodies (intrabodies) and their therapeutic potential. , 2008, Handbook of experimental pharmacology.

[34]  Debjani Paul,et al.  Label-free sub-picomolar protein detection with field-effect transistors. , 2010, Analytical chemistry.

[35]  K. Gull,et al.  A Protein-Protein Interaction Map of the Trypanosoma brucei Paraflagellar Rod , 2009, PloS one.

[36]  M. Bickle,et al.  Peptide aptamers for small molecule drug discovery. , 2009, Methods in molecular biology.

[37]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[38]  Julie M. Sahalie,et al.  An experimentally derived confidence score for binary protein-protein interactions , 2008, Nature Methods.

[39]  A. Barabasi,et al.  A Protein–Protein Interaction Network for Human Inherited Ataxias and Disorders of Purkinje Cell Degeneration , 2006, Cell.

[40]  P. Chanda,et al.  Identification and characterization of small molecule modulators of KChIP/Kv4 function. , 2005, Bioorganic & medicinal chemistry.

[41]  S. Hawkins,et al.  Chemical Genetics , 1973, Nature.

[42]  Ariel S. Schwartz,et al.  Cost effective strategies for completing the Interactome , 2008, Nature Methods.

[43]  T. Blundell,et al.  Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia. , 2009, Cancer research.

[44]  W. Abida,et al.  Dexamethasone−Methotrexate: An Efficient Chemical Inducer of Protein Dimerization In Vivo , 2000 .

[45]  R. Brent,et al.  A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor , 1985, Cell.

[46]  E. Golemis,et al.  Resolving the network of cell signaling pathways using the evolving yeast two-hybrid system. , 2008, BioTechniques.

[47]  S. Laurenson,et al.  Development of peptide aptamer microarrays for detection of HPV16 oncoproteins in cell extracts. , 2011, Analytical biochemistry.

[48]  B. de Chassey,et al.  An Antiproliferative Genetic Screening Identifies a Peptide Aptamer That Targets Calcineurin and Up-regulates Its Activity* , 2007, Molecular & Cellular Proteomics.

[49]  A. Barberis,et al.  Quenching accumulation of toxic galactose-1-phosphate as a system to select disruption of protein-protein interactions in vivo. , 2004, BioTechniques.

[50]  C. Rommel,et al.  Decompartmentalizing target validation—thinking outside the pipeline boxes , 2006, Journal of Molecular Medicine.

[51]  Olivier Sperandio,et al.  Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.

[52]  G. Kroemer,et al.  Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. , 2011, Cancer research.

[53]  M. Bickle,et al.  A Comparative Analysis of Perturbations Caused by a Gene Knock-out, a Dominant Negative Allele, and a Set of Peptide Aptamers*S , 2007, Molecular & Cellular Proteomics.

[54]  Agrobacterium tumefaciens-mediated transformation of filamentous fungi , 1998, Nature Biotechnology.

[55]  P. Colas,et al.  High-throughput screening assays to discover small-molecule inhibitors of protein interactions. , 2008, Current drug discovery technologies.

[56]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[57]  Hualiang Jiang,et al.  The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation , 2009, Acta Pharmacologica Sinica.

[58]  Julie A. Hines,et al.  A proteome-wide protein interaction map for Campylobacter jejuni , 2007, Genome Biology.

[59]  A. Colman-Lerner,et al.  "Mutagenesis" by peptide aptamers identifies genetic network members and pathway connections. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  Yuren Wang,et al.  A Dual Luciferase Multiplexed High-Throughput Screening Platform for Protein-Protein Interactions , 2003, Journal of biomolecular screening.

[61]  Jan Tavernier,et al.  Strategies towards high-quality binary protein interactome maps. , 2010, Journal of proteomics.

[62]  Jingkai Yu,et al.  Combining multiple positive training sets to generate confidence scores for protein–protein interactions , 2008, Bioinform..

[63]  K. Lund,et al.  Identification of protein interaction antagonists using the repressed transactivator two-hybrid system. , 2007, BioTechniques.

[64]  John S Lazo,et al.  Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.

[65]  S. L. Wong,et al.  Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.

[66]  Stanley Fields,et al.  Interactive learning: Lessons from two hybrids over two decades , 2009, Proteomics.

[67]  David P. Lane,et al.  Translating p53 into the clinic , 2010, Nature Reviews Clinical Oncology.

[68]  M. Vidal,et al.  Edgetic perturbation models of human inherited disorders , 2009, Molecular systems biology.

[69]  Sebastian Meier-Ewert,et al.  A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. , 2004, Chemistry & biology.

[70]  P. Uetz,et al.  The Binary Protein Interactome of Treponema pallidum – The Syphilis Spirochete , 2008, PloS one.

[71]  Bruno O Villoutreix,et al.  A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally. , 2008, The Journal of allergy and clinical immunology.

[72]  B. Groner,et al.  Monomeric Recombinant Peptide Aptamers Are Required for Efficient Intracellular Uptake and Target Inhibition , 2008, Molecular Cancer Research.

[73]  E J Licitra,et al.  A three-hybrid system for detecting small ligand-protein receptor interactions. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[74]  Bernd Groner,et al.  Peptide aptamer libraries. , 2008, Combinatorial chemistry & high throughput screening.

[75]  P. Colas,et al.  Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers , 2011, Oncogene.

[76]  Philippe Roche,et al.  Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database , 2010, PloS one.

[77]  Jie Zhang,et al.  Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[78]  L. Hutchinson,et al.  High drug attrition rates—where are we going wrong? , 2011, Nature Reviews Clinical Oncology.

[79]  Caroline C. Friedel,et al.  Analysis of Intraviral Protein-Protein Interactions of the SARS Coronavirus ORFeome , 2007, PloS one.

[80]  W. Childers,et al.  Disruption of Kv1.1 N-type inactivation by novel small molecule inhibitors (disinactivators). , 2008, Bioorganic & medicinal chemistry.

[81]  S. Fields,et al.  A novel genetic system to detect protein–protein interactions , 1989, Nature.

[82]  M. Vidal,et al.  Hepatitis C virus infection protein network , 2008, Molecular systems biology.

[83]  Anne-Claude Gavin,et al.  Recent advances in charting protein-protein interaction: mass spectrometry-based approaches. , 2011, Current opinion in biotechnology.

[84]  Peter Uetz,et al.  Improving yeast two-hybrid screening systems. , 2008, Briefings in functional genomics & proteomics.

[85]  S. Fields,et al.  The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[86]  R. Brent,et al.  Understanding gene and allele function with two-hybrid methods. , 1997, Annual review of genetics.

[87]  Peter Uetz,et al.  Improving the yeast two-hybrid system with permutated fusions proteins: the Varicella Zoster Virus interactome , 2010, Proteome Science.

[88]  K. Shokat,et al.  Chemical Genetics: Where Genetics and Pharmacology Meet , 2007, Cell.

[89]  V. Tan,et al.  First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors. , 2011, Biotechnology journal.

[90]  P. Secchiero,et al.  Recent advances in the therapeutic perspectives of Nutlin-3. , 2011, Current pharmaceutical design.

[91]  Julie M. Sahalie,et al.  Supplementary Figure and Table Legends , 2022 .

[92]  Roger Brent,et al.  Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2 , 1996, Nature.

[93]  F. Hoppe-Seyler,et al.  Isolation of peptides blocking the function of anti-apoptotic Livin protein , 2010, Cellular and Molecular Life Sciences.

[94]  Robert W. Shafer,et al.  Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C , 2010, Viruses.